Best of ASH Annual Meeting & Exposition | Conference

Amitkumar Mehta, MD, detailed encouraging data presented at the 63rd ASH Annual Meeting for treating mantle cell lymphoma.

Michael R. Bishop, MD, discussed details from the ZUMA-7 and TRANSFORM trials that were presented at the 63rd ASH Annual Meeting.

Yael Cohen, MD, sat down with CancerNetwork® to spotlight a number of promising treatments that are under investigation for patients with heavily-pretreated multiple myeloma.

At the 2021 ASH Annual Meeting, Yelena Ginzburg, MD, spoke about presentations she found most groundbreaking.

In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, talks about daratumumab-based quadruplet therapies being evaluated in clinical trials and the potential impact they’ll have on the multiple myeloma treatment landscape.

Matthew S. Davids, MD, spoke about which abstracts presented at ASH 2021 he felt were most important.

Lindsey Roeker, MD, spoke about data presented at ASH 2021 and what she thought to be most interesting.

When asked about abstracts he thinks have the greatest potential to impact the standard of care in myeloma, Rafael Fonseca, MD, looked to emerging cellular therapies, specifically ciltacabtagene autoleucel for the treatment of heavily pretreated disease.

Wolf touched on the implications of results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma.

A study of the effect of intravenous immunoglobulin (IVIG) on infections in patients with multiple myeloma receiving daratumumab indicated that hypogammaglobulinemia was nearly universal during treatment, suggesting a role for IVIG.